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Summary Introduction
UDP-galactose-4-epimerase (GALE) is a highly conserved UDP-galactose-4-epimerase (GALE; E.C.5.1.3.2) cata-
enzyme that catalyzes the interconversion of UDP-galac- lyzes the third step of the Leloir pathway of galactose
tose and UDP-glucose. Impairment of this enzyme in hu- metabolism (Frey 1996) (ﬁg. 1). Impairment of this en-
mans results in one of two clinically distinct forms of epi- zyme in humans results in one of two clinically distinct
merase-deﬁciency galactosemia—one benign, the other forms of autosomal recessive epimerase-deﬁciency galac-
severe. Themolecular and biochemical distinction between tosemia (MIM 230350). A clinically benign, or ‘‘periph-
these disorders remains unknown. To enable structural eral,’’ form was ﬁrst reported by Gitzelmann (Gitzel-
and functional studies of both wild-type and patient-de- mann 1972; Gitzelmann and Steimann 1973), on the
rived alleles of humanGALE (hGALE), we have developed basis of studies of asymptomatic patients who exhibited
and applied a null-background yeast expression system for no detectable GALE activity in red blood cells (RBC)
the human enzyme. We have demonstrated that wild-type but who exhibited normal activity in other tissues. A
hGALE sequences phenotypically complement a yeast second, much rarer and ‘‘generalized’’ form of the disor-
gal10 deletion, and we have biochemically characterized der was ﬁrst reported by Holton et al. (1981), on the
the wild-type human enzyme isolated from these cells. Fur- basis of studies of a severely affected patient demon-
thermore, we have expressed and characterized two mu- strating undetectable levels of GALE activity in all tis-
tant alleles, L183P-hGALE and N34S-hGALE, both de- sues examined. Limited population studies suggest that
rived from a patient with no detectable GALE activity the peripheral form may be quite common, at least in
in red blood cells but with Ç14% activity in cultured some ethnic groups (Alano et al., in press). In contrast,
lymphoblasts. Analyses of crude extracts of yeast express- only two cases of generalized epimerase-deﬁciency have
ing L183P-hGALE demonstrated 4% wild-type activity been reported (Holton et al. 1981; Sardharwalla et al.
and 6% wild-type abundance. Extracts of yeast expressing 1988). The molecular and biochemical distinction be-
N34S-hGALE demonstratedÇ70% wild-type activity and tween the peripheral and generalized forms of epimerase
normal abundance. However, yeast coexpressing both deﬁciency remains unknown.
L183P-hGALE and N34S-hGALE exhibited only Ç7% Wild-type GALE enzymes have been isolated and/or
wild-type levels of activity, thereby conﬁrming the func- characterized in a variety of species and tissues (e.g.,
tional impact of both substitutions and raising the intrigu- see Maley and Maley 1959; Wilson and Hogness 1964,
ing possibility that some form of dominant-negative inter- 1969; Darrow and Rodstrom 1968; Salo et al. 1968;
action may exist between the mutant alleles found in this Tsai et al. 1970; Langer and Glaser 1974; Piller et al.
patient. The results reported here establish the utility of the 1983 Frey 1996; Thoden et al. 1996), including humans
yeast-based hGALE-expression system and set the stage for (Bergren et al. 1973; Mitchell et al. 1975). All of these
more-detailed studies of this important enzyme and its role GALE enzymes are believed to function as homodimers
in epimerase-deﬁciency galactosemia.
(e.g., see Frey 1996; Langer and Glaser 1974; Thoden et
al. 1996), and both biochemical and structural evidence
from studies of the Escherichia coli enzyme now indicate
that one NAD/ is bound per subunit (Frey 1996; Tho-
den et al. 1996). It is interesting to note that, althoughReceived March 7, 1997; accepted for publication July 1, 1997.
the enzymes isolated from E. coli and yeast do not re-Address for correspondence and reprints: Dr. Judith L. Fridovich-
Keil, Department of Genetics, Emory University School of Medicine, quire exogenously added NAD/ for function, all mam-
1462 Clifton Road N.E., Atlanta, GA 30322. E-mail: jfridov@emory malian GALE enzymes do require exogenous NAD/
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diet, with no hepatomegally, liver disease, vomiting, or
acidosis, and although RBC galactose-1-phosphate was
elevated in infancy, with time these values decreased to
the normal range. Urinary galactitol, measured at age
26 mo, was within normal limits, consistent with a diag-
nosis of peripheral epimerase deﬁciency. At Ç1 year of
age the proband began experiencing delays in gross mo-
tor development, and at age 5 years he exhibits mild
to moderate mental retardation with global delays inFigure 1 Leloir pathway of galactose metabolism
language and cognitive abilities, but otherwise he is
healthy and well. Blood samples from the proband and
both parents were collected as described elsewhere (A.to interconvert only UDP-glucose and UDP-galactose
Alano, S. Almashanu, J. M. Chinsky, P. Costeas, M. G.(Darrow and Rodstrom 1968; Salo et al. 1968; Piller et
Blitzer, E. A. Wulfsberg, T. M. Cowan, unpublishedal. 1983), puriﬁed mammalian GALE enzymes appear
data), with appropriate informed consent. This researchto be bifunctional, demonstrating the ability to intercon-
project was approved by the institutional review boardvert both UDP-glucose/UDP-galactose and UDP-N ace-
at Emory University.tylglucosamine/UDP-N acetylgalactosamine (Maley and
Maley 1959; Piller et al. 1983; Kingsley et al. 1986). Yeast Strains, Plasmids, and Expression Studies
Considering the pivotal role of these latter substrates in
All recombinant DNA manipulations were performedcellular assembly of complex polysaccharides and other
according to standard techniques (Sambrook et al.glycosylated macromolecules, the biological signiﬁcance
1989) and utilized E. coli strain XL1-Blue (Stratagene).of the mammalian GALE enzyme clearly extends beyond
The yeast strain yBBQ1, which carries a disruption ofthe catabolism of dietary galactose.
the genomic gal80 locus, was derived from strainA human cDNA encoding wild-type human GALE
YM366 (MATa gal10-120 ura3-52 his3-200 ade2-101(hGALE) was recently cloned and characterized by
lys2-801 tyr1-501; generously donated by Dr. MarkDaude et al. (1995), thereby enabling molecular studies
Johnston, Washington University School of Medicine,of mutations associated with epimerase-deﬁciency galac-
St. Louis) by one-step gene replacement via homologoustosemia. To facilitate studies of both wild-type and pa-
recombination (Rothstein 1991). The gal80 disruptiontient-derived mutant forms of hGALE, we have devel-
cassette used in this procedure carried the Alani-Kleck-oped a null-background yeast expression system for the
ner URA3 cassette (Alani et al. 1987) subcloned in placehuman enzyme. We have utilized this system to express,
of a 600-bp BglII fragment, which had been removed.isolate, and characterize wild-type hGALE, as well as
The wild-type hGALE-coding sequence was obtained bytwo patient-derived mutant alleles each modeled in the
standard PCR ampliﬁcation of cDNA isolated from con-homozygous, heterozygous, and compound-heterozy-
trol lymphoblasts by use of a 16:1 mixture of Taq andgous states, comparing the results with those observed
Pfu DNA polymerases and the primers 5-GCCGGA-in corresponding family members. The results reported
ATTCATAAAAATGGCAGAGAAGGTGCTGG-3here represent the ﬁrst biochemical characterization of
(forward) and 5-GCGGTCGACGCTGCTTTTCCT-mutant forms of hGALE associated with epimerase-de-
GGTCCTTGG-3 (reverse). The wild-type rat GALE-ﬁciency galactosemia.
coding sequence was obtained similarly by PCR ampli-
ﬁcation using as template the rat cDNA clone (Zesch-Subjects and Methods
nigk et al. 1990) generously donated by Drs. Zeschnigk
Patient and Starzinski-Powitz, with primers 5-GCCGGAATT-
CATAAAAATGGAGGAGAAGGTGCTCGTC-3 (for-The proband is a 5-year-old male born to a Caucasian
mother and a Pakistani father. His neonatal course was ward) and 5-GCGGTCGACTGTAGGGTCCTGTGG-
CGGCTGC-3 (reverse). These two sets of primersunremarkable, and he remained on a lactose-containing
diet. Results of newborn screening at 6 and 9 d of age introduced unique 5 EcoRI and 3 SalI sites onto the
ends of both ampliﬁed fragments to facilitate subclon-revealed abnormally elevated galactose sugars but
normal UDP-galactose-1-phosphate uridylyltransferase ing. Sequences encoding the HIS6 and 12CA5 epitope
tags also were introduced onto the 3 end of the hGALE-(GALT) activity. Follow-up studies conﬁrmed normal
erythrocyte GALT activity, elevated levels of galactose- coding sequence by PCR (reverse primers 5-GCCGTC-
GACTCAATGGTGATGGTGATGGTGGGCTTG-1-phosphate, negative urinary reducing sugars, and no
detectable erythrocyte GALE activity (A. Alano, S. Al- CGT GCCAAAGCCTG-3 and 5-GCCGTCGACTCA-
AGCGTAGTCTGGGACGTCG TATGGGTAGGC-mashanu, J. M. Chinsky, P. Costeas, M. G. Blitzer, E.
A. Wulfsberg, T. M. Cowan, unpublished data). The TTGCGTGCCAAAGCCTG-3, respectively); all resul-
tant subclones were conﬁrmed by dideoxy sequencing.child remained clinically well on a lactose-containing
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All GALE alleles to be transformed singly into yeast From lymphoblasts.—GALE activity levels in extracts
of cultured lymphoblasts were evaluated essentially aswere subcloned into the low-copy-number expression
plasmid pBQy1, which was derived from pPEy1 (Fridov- described above, except that the ﬁrst reaction contained
0.22 mM UDP-gal, 1 mM NAD/, 10 mM sodium py-ich-Keil et al. 1995b) by replacement of the LEU2
marker by HIS3. To enable cotransformation and there- ruvate, 100 mM glycyl glycine pH 8.7, and 0-0.08 ml
cell lysate (at 1.5–2.0 mg total protein/ml). To stopfore coexpression of pairs of hGALE alleles in yeast,
the appropriate hGALE sequences were introduced into each reaction, samples were boiled for 2 min and were
centrifuged, and 0.15 ml supernatant was then used forboth pBQy1 and pBQy4, which are identical except for
the markers that they carry (HIS3 and URA3, respec- the second reaction. Total protein concentration in each
extract was determined by the method of Lowry et al.tively). All yeast transformations, culture manipulations,
and extract preparations were performed according to (1951).
From yeast extracts.—GALE activity was evaluatedstandard protocols as described elsewhere (Fridovich-
Keil and Jinks-Robertson 1993; Fridovich-Keil et al. in yeast extracts by determination of the conversion of
substrate to product, as modiﬁed from the method of1995a; Fridovich-Keil et al. 1995b; Elsevier et al. 1996;
Quimby et al. 1996). Merrill et al. (1976). Except where otherwise noted,
each 25-ml reaction mixture contained 5 ml premix
Lymphoblast Transformation, Culture, and Analysis (3.3 mM [0.1 mCi] (14C)-UDP-galactose; Amersham
CFB129), 2 mM UDP-galactose (cold), 2 M glycineTransformed lymphoblasts were established by use of
a modiﬁcation of the procedure of Anderson and Gusella buffer pH 8.7), 5 ml 20 mM NAD/, and 15 ml yeast
extract diluted in a buffer of 20 mM Hepes/KOH, pH(1984). White blood cells were separated in a Ficoll
gradient, and the buffy coat containing mononuclear 7.5, 1 mM DTT, and 0.3 mg BSA/ml. All reactions were
incubated at 37C for 30 min, were stopped by boilingleukocytes was resuspended in RPMI 1640 (containing
FBS, L-glutamine, antibiotic-antimycotic, phytohemag- for 5 min, and then the product was centrifuged for 5
min at room temperature to pellet insolubles. Finally,glutinin-M, and interleukin-2) and was transformed
with Epstein-Barr virus (EBV). For biochemical analysis, 10 ml each reaction mixture was spotted onto a PEI-
cellulose thin-layer chromatography (TLC) plate (Baker)expanded cultures of cells were pelleted by centrifuga-
tion, were washed once in 0.85%NaCl, and were stored and dried in a 37C incubator for 30–60 min. The chro-
matogram was run in a single dimension for 7-20 h,at 080C until assay. For enzyme assays, thawed cell
pellets were disrupted by sonication in deionized water. with a solvent of 1.5 mM Na2B4O7, 5 mM H3BO4, and
25% ethylene glycol. Paper toweling was clipped at the
GALE Activity Assays top of each TLC plate to extend the effective ‘‘run time’’
of each assay. After chromatography, each plate wasFrom RBC hemolysates.—GALE was assayed in RBC
by use of a two-step ﬂuorometric method (modiﬁed and removed from the solvent and was air-dried, and areas
containing radioactive material were visualized andadapted from Beutler [1975] and Gitzelmann and Stei-
mann [1973]) that involved (1) epimerization of UDP- quantitated by use of a Molecular Dynamics Phos-
phorimager.galactose to UDP-glucose, followed by (2) conversion
of the UDP-glucose and exogenous NAD/ to UDP-
Enzyme Puriﬁcation and Kineticsglucuronate and NADH, which was monitored ﬂuoro-
metrically. The ﬁrst reaction (0.1 ml patient hemolysate Yeast extracts were prepared from 1-liter cultures
grown at 30C to midlogarithmic phase in YPGal, werein 300 mM glycine and 1.67 mM NAD/, with 0.8 mM
UDP-galactose in a ﬁnal volume of 0.3 ml) was incu- harvested by centrifugation at 4C, and were lysed as
described elsewhere (Fridovich-Keil and Jinks-Robert-bated at 37C for 20 min and was stopped by boiling.
After centrifugation to pellet insolubles, 0.03 ml super- son 1993; Quimby et al. 1996). Nickel-afﬁnity puriﬁca-
tion of HIS6-tagged proteins was performed essentiallynatant was added to the second reaction, which also
contained 0.74 mM NAD/, 74 mM glycine, and as described elsewhere (Quimby et al. 1996), except that
the binding buffer contained 50 mM imidizole, the wash0.00825 U UDP-glucose dehydrogenase (Sigma U5500),
in a total volume of 1.335 ml. This second reaction was buffer contained 60 mM imidizole, and the protein-elu-
tion buffer contained 200 mM imidizole. Near homoge-incubated at room temperature for 1 h, and ﬂuorescence
was read at excitation-wavelength 360 nm and emis- neity of each sample was demonstrated by one dimen-
sional SDS-PAGE followed by staining with Coomassiesion-wavelength 460 nm. Data obtained were then con-
verted into units of mmol UDP-glu/g hemoglobin/h, as blue (data not shown). Concentrations of both crude
yeast lysates and puriﬁed proteins were determined bydescribed elsewhere (A. Alano, S. Almashanu, J. M.
Chinsky, P. Costeas, M. G. Blitzer, E. A. Wulfsberg, use of the Bio-Rad protein-assay reagent, with BSA as
the standard. Kinetic analyses of each protein were per-T. M. Cowan, unpublished data). Hemoglobin concen-
tration was determined by use of Drabkins reagent formed in duplicate over a range of 10 different concen-
trations of substrate (UDP-galactose) (with NAD/ held(Sigma 525-2) as described by the manufacturer.
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tution N34S; a TrC transition at 632, predicting the
substitution V180A; and a TrC transition at 641, pre-
dicting the substitution L183P (A. Alano, S. Almashanu,
J. M. Chinsky, P. Costeas, M. G. Blitzer, E. A. Wulfs-
berg, T. M. Cowan, unpublished data). Direct sequenc-
ing of cDNA samples, followed by mismatch PCR analy-
ses of genomic DNA, identiﬁed single copies of the N34S
substitution in both the proband and his mother and
identiﬁed single copies of the L183P substitution in both
the proband and his father (ﬁg. 2). DNA mutations cor-
responding to both the N34S and L183P predicted sub-
stitutions were not seen in any of eight control alleles.
In contrast, the TrC transition at 632 was found inFigure 2 Family pedigree. Deduced GALE genotypes are indi-
all alleles tested, representing both control and affectedcated below each symbol. RBC and lymphoblast GALE activity levels
also are indicated, where available. individuals (A. Alano, S. Almashanu, J. M. Chinsky,
P. Costeas, M. G. Blitzer, E. A. Wulfsberg, T. M.
Cowan, unpublished data). This base change also was
found in the wild-type hGALE allele used in the yeastconstant at 4 mM) and eight different concentrations of
expression system. We therefore conclude that the tran-NAD/ (with UDP-galactose held constant at 0.4 mM).
sition at position 632 is likely to be a polymorphismTo control for potential differences between individual
and, indeed, that the sequence reported here may actu-puriﬁcations, analyses were performed on samples de-
ally reﬂect the predominant allele.rived from each of three separate puriﬁcations for each
A Yeast Expression System for hGALEprotein.
We have exploited the technical facility of Saccharo-
Western Blot Analysis myces cerevisiae to create a null-background haploid
Western blot analyses were performed as described strain of yeast, yBBQ1, that carries a genomic deletion
elsewhere (Fridovich-Keil et al. 1995b; Elsevier et al. in the endogenous gal10 locus and that therefore ex-
1996; Quimby et al. 1996). Proteins were detected by presses no endogenous UDP-galactose-4-epimerase.
use of the 12CA5 monoclonal antibody (Boehringer yBBQ1 also carries genomic disruptions of its his3 and
Mannheim) at 1 mg/ml. To control for loading of lanes, ura3 loci, to enable selection of transformants, and of
a rabbit polyclonal antiserum generated against yeast the gal80 repressor locus, to enable high-level expression
cyclophilin A (Zydowsky et al. 1992) also was included, from the plasmid-borne GAL10 promoter even in the
at a dilution of 1:10,000. The secondary antibodies used absence of galactose (Johnston 1987).
were sheep anti-mouse Ig (for 12CA5) and goat anti- As a ﬁrst test of the ability of plasmid-encoded mam-
rabbit Ig (for cyclophilin), both coupled to horseradish malian GALE enzymes to function in yeast, yBBQ1 cells
peroxidase (Amersham). Signals were visualized by use were transformed with yeast low-copy number plasmids
of the ECL kit from Amersham and were quantitated encoding either wild-type rat (Zeschnigk et al. 1990)
by use of a Molecular Dynamics Personal Densitometer or hGALE. Both wild-type yeast GAL10 and plasmid
SI scanning laser densitometer. backbone alone also were introduced as controls. All
transformants were selected initially on the basis of plas-
mid-encoded histidine prototrophy, and GAL/ pheno-Results
type was scored by growth in liquid medium containing
Pedigree Analysis and Biochemical Evaluation of galactose as the sole carbon source (Sgal-his). All GALE-
Patient Samples expressing transformants grew well; the negative control
Fresh peripheral blood was collected from each of the did not (ﬁg. 3). These data conﬁrm that both the rat
individuals illustrated in ﬁgure 2; RBC GALE activity and wild-type hGALE sequences produce functional
for the proband was undetectable; and the correspond- products in yeast.
ing levels in both parents were signiﬁcantly reduced, As a more direct test of the functional capacity of
consistent with their status as obligate carriers. Prelimi- hGALE expressed in yeast, whole-cell lysates were pre-
nary GALE activity assays also were performed on ex- pared from the appropriate transformants and were as-
tracts of EBV-immortalized lymphoblasts from the pro- sayed for enzymatic activity in the presence or absence
band (ﬁg. 2). of exogenous NAD/ (ﬁg. 4). As expected (Darrow and
Molecular analyses of the GALE-coding sequences in Rodstrom 1968), yeast GALE demonstrated full activity
the patient and both parents revealed three base substi- even in the absence of exogenous NAD/, whereas
tutions relative to the published sequence (Daude et al. hGALE activity demonstrated a strong dependence on
exogenously added NAD/ (ﬁg. 4).1995): an ArG transition at 194, predicting the substi-
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Figure 4 Effect of NAD/ on GALE activity in extracts of yeast
expressing either wild-type hGALE (circles), wild-type yeast GALE
(squares), or no GALE (triangles). Duplicate extracts (unblackened
and blackened symbols) were assayed for GALE activity at each of
the (exogenous) NAD/ concentrations indicated, as described in Sub-
jects and Methods. The concentration of exogenous UDP-galactose
was held constant at 0.4 mM.
Figure 3 Yeast growth in liquid medium containing galactose
as the sole carbon source. yBBQ1 cells transformed with pBQy1-
derivative plasmids encoding each of the GALE alleles indicated were
Characterization of N34S-hGALE and L183P-hGALEinoculated into selective medium at time 0, incubated at 30C with
Expressed in Yeastshaking, and monitored over time by optical density at 600 nm. All
four strains grew well in medium containing glucose (data not shown). To assess the functional signiﬁcance of both the
L183P and N34S substitutions, each corresponding mu-
Isolation and Characterization of Wild-Type hGALE
Expressed in Yeast
To facilitate recognition and isolation of hGALE ex-
pressed in yeast, we engineered two small tags,
(HA)12CA5 (Wilson et al. 1984) and HIS6 (e.g., see
Gentz et al. 1989), onto its C-terminus. To ensure that
neither tag impaired activity of the corresponding fusion
protein, activity assays were performed on extracts of
yeast expressing either untagged, 12CA5-tagged, or
HIS6-tagged hGALE. As illustrated, all three forms of
hGALE demonstrated indistinguishable levels of activity
(ﬁg. 5). Speciﬁcity of the 12CA5 antibody was conﬁrmed
by SDS-PAGE western blot analysis of crude yeast ly-
sates (ﬁg. 6).
Kinetic studies were performed by use of the wild-
type HIS6-tagged hGALE protein puriﬁed to near homo-
geneity. Kinetic constants were determined by ﬁtting the
data to a Lineweaver-Burke plot (Robyt and White
1990) (table 1).
The effect of exogenous NAD/ on activity of the puri-
ﬁed hGALE protein was evaluated over an NAD/ con-
Figure 5 Activities of wild-type and mutant hGALE proteinscentration range of 0–40 mM, with UDP-galactose held
expressed in yeast. Crude lysates prepared from cultures expressingconstant at 0.4 mM. In the absence of exogenous NAD/,
each of the GALE proteins indicated were analyzed for activity as
no GALE activity was detected. As increasing amounts described in Subjects and Methods. Values plotted represent averages
of NAD/ were added, the apparent GALE activity rose { SD (n Å 8). Average activity levels normalized to the human wild-
type (untagged) are given in parentheses.dramatically (ﬁg. 7).
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Figure 7 Effects of NAD/ on puriﬁed preparations of wild-type
and N34S-hGALE. Assays were performed as described in Subjects
and Methods, with exogenous UDP-galactose held constant at 0.4Figure 6 A, Western blot analysis of wild-type, N34S-hGALE,
mM and with exogenous NAD/ concentration varied as indicated.and L183P-hGALE proteins expressed in yeast. As indicated, increas-
For each protein, unblackened and blackened symbols represent dataing levels of the appropriate yeast extracts were loaded onto adjacent
derived from independent experiments.lanes of an SDS-polyacrylamide gel, were electrophoresed, and then
were analyzed with respect to GALE abundance by western blot using
a mouse monoclonal antibody against 12CA5, as described in Subjects
and Methods. As a control for loading, a rabbit polyclonal antiserum
the wild-type enzyme, no detectable perturbations ofdirected against the endogenous yeast protein cyclophilin (Zydowsky
et al. 1992) also was included in this experiment. B, Quantitative activity were observed (data not shown).
analysis of the results presented in A. Values plotted represent normal- Western blot analyses of whole-cell lysates represent-
ized averages { SD of the 12CA5:cyclophilin signal ratio for each ing 12CA5-tagged mutant and wild-type hGALE pro-
extract.
teins were performed to evaluate the relative impact of
each substitution on hGALE steady-state abundance
(ﬁg. 6). As a control for loading of lanes, each blot also
tation was introduced into the otherwise wild-type
was probed with a rabbit polyclonal antiserum directed
hGALE sequence, and the resultant alleles were ex-
against endogenous yeast cyclophilin (Zydowsky et al.
pressed in yeast. Biochemical analyses of crude cell ex-
1992). As illustrated in ﬁgure 6, steady-state N34S-
tracts demonstrated that, under normal assay condi-
hGALE levels were indistinguishable from those of the
tions, N34S-hGALE retained Ç70% wild-type activity
wild-type protein, suggesting that the mild activity im-
and L183P-hGALE retained Ç4% wild-type activity
pairment associated with this substitution in crude cell
(ﬁg. 5). Both mutant proteins also were both 12CA5
lysates (ﬁg. 5) reﬂected a difference in function of the
tagged and HIS6 tagged, and, as has been described for
enzyme, rather than abundance of the protein. In con-
trast, L183P-hGALE abundance was reduced to only
Ç6% of wild-type levels, thereby accounting for most
Table 1
if not all of the activity loss (ﬁg. 5).
Speciﬁc Activity and Apparent Km Values for Puriﬁed Wild-Type To characterize more precisely any kinetic effects of
and N34S-hGALE Proteins Isolated from Yeast the N34S substitution on hGALE function, HIS6-N34S-
hGALE/N34S-hGALE was puriﬁed from yeast lysates
Apparent
to near homogeneity. Kinetic analyses of the puriﬁedUDP-gal Km Speciﬁc Activity
enzyme under conditions of ﬁxed exogenous NAD/ (4hGALE Derivative (mM) (mmol UDP-glu/mg protein/min)
mM) demonstrated both Michaelis constant (Km) and
Wild type 0.23 { 0.06 265 { 81 speciﬁc-activity values indistinguishable from those of
N34S 0.33 { 0.08 275 { 100 the wild type (table 1). Because the E. coli GALE residue
N32, corresponding to N34 in hGALE, is predicted toNOTE.—Assays to determine the UDP-galactoseKm were performed
form a hydrogen bond with the adenine ring of boundat a ﬁxed concentration of 4 mM NAD/. All values are averages {SD
of three or more independent analyses. NAD/ (Thoden et al. 1996), potential effects of the
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different plasmids each encoding N34S-hGALE; GALE
activity detected in these cells was 61% ({0.01; n Å 4)
of that in cells coexpressing two wild-type alleles,
thereby eliminating this possibility.
Discussion
That GALE activity was detectable in immortalized
lymphoblasts prepared from the proband reported here
is not surprising; Mitchell et al. (1975) observed essen-
tially normal GALE activity in lymphoblasts derived
from a number of different patients with peripheral epi-
merase-deﬁciency galactosemia. Contrary to that report,
however, we detected reduced rather than normal levels
of activity, thereby raising the possibility that the epi-
merase deﬁciency in this patient may not be entirely
peripheral. Clearly, studies of the GALE activities in
additional tissues will be required to address this issue.
Published values for the speciﬁc activities of mamma-
Figure 8 Activities of coexpressed wild-type and mutant hGALE lian GALE enzymes range from 0.65 mmol UDP-glu/mg
proteins expressed in yeast. Crude lysates prepared from cultures ex- protein/min (Maxwell 1957) to 315 { 25.2 mmol UDP-
pressing each of the pairs of GALE alleles indicated were analyzed for
glu/mg protein/min (Piller et al. 1983). Presumably thisactivity as described in Subjects andMethods. Values plotted represent
range reﬂects differences in either purity or partial inacti-averages { SD (n § 6). Average activity levels normalized to the
human wild type are given in parentheses. vation of the enzymes during isolation. We report here
a speciﬁc activity of 265 mmol UDP-glu/mg protein/min
(table 1), demonstrating that expression of the human
enzyme in yeast did not compromise the catalytic capac-N34S substitution on NAD/ binding also were investi-
ity of the enzyme.gated. Kinetic analyses were performed under conditions
Differences are apparent in the substrate Km valuesof ﬁxed substrate concentration and varying amounts
reported here and elsewhere. The UDP-galactose Km val-of exogenous NAD/. The results of these assays revealed
ues reported for GALE enzymes from calf liver (Maxwella more-than-fourfold increase over wild type in the
1957), bovine mammary gland (Tsai et al. 1970), por-amount of exogenous NAD/ required to achieve half-
cine submaxillary gland (Piller et al. 1983), and humanmaximal activity (ﬁg. 7).
ﬁbroblasts (Chacko et al. 1972) are 0.02–0.05 mM; the
Coexpression of Mutant and Wild-Type Alleles apparent UDP-galactose Km reported here is 0.23{ 0.06
mM (table 1). Variations in either sample purity or assayTo evaluate potential interactions between GALE al-
leles, we have coexpressed both untagged N34S-hGALE method may account for much of this difference. For
example, in some cases crude ﬁbroblast lysates ratherand untagged L183P-hGALE in yeast, modeling both
the heterozygous (parents) and compound-heterozygous than puriﬁed enzymes were analyzed, so that contribu-
tions from endogenous pools of substrate or other fac-(proband) states. Control experiments demonstrated
that both low-copy number plasmids used in these stud- tors could not be discounted (Chacko et al. 1972). It is
interesting to note that the UDP-galactose Km reportedies expressed indistinguishable levels of GALE protein
(data not shown). for puriﬁed E. coli GALE is 0.16 mM (Wilson and Hog-
ness 1964), a value similar to the one reported here.Activity assays on crude lysates demonstrated that,
as expected, cells coexpressing two copies of wild-type The results reported here (ﬁgs. 4 and 7) clearly demon-
strate that the previously observed differential depend-hGALE expressed twice the level of activity seen in cells
expressing hGALE from a single copy (ﬁgs. 5 and 8). encies of yeast and mammalian GALE enzymes on exog-
enous NAD/ (Maxwell 1957; Darrow and RodstromIn contrast, cells coexpressing either each mutant allele
together with the wild type or the two mutant alleles in 1968; Salo et al. 1968; Tsai et al. 1970; Langer and
Glaser 1974) reﬂect properties intrinsic to these pro-combination demonstrated activities that were signiﬁ-
cantly reduced (ﬁg. 8). These data raise the intriguing teins, rather than differences in the cellular environments
in which these enzymes normally are synthesized. Aspossibility that some form of dominant-negative interac-
tion may exist between the mutant alleles identiﬁed in described above for speciﬁc activity and Km, differences
in sample preparation, purity, and/or methods of analy-this family. To test the possibility that diminished activ-
ity was an artifactual consequence of double rather than sis also may account for apparent differences between
previous reports and our observations concerning thesingle transformation, we cotransformed yeast with two
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Beutler E (1975) Red cell metabolism: a manual of biochemicallevel of exogenous NAD/ required for half-maximal ac-
methods, 3d ed. Grume & Stratton, Orlandotivity of hGALE (ﬁg. 7).
Chacko CM, McCrone L, Nadler HL (1972) A study of galac-Our observation that puriﬁed N34S-hGALE required
tokinase and glucose 4-epimerase from normal and galactos-more than four times as much NAD/ to achieve half-
emic skin ﬁbroblasts. Biochim Biophys Acta 284:552–555maximal activity as did the wild-type enzyme is particu-
Darrow RA, Rodstrom R (1968) Puriﬁcation and properties
larly intriguing, especially considering that Mitchell et of uridine diphosphate galactose 4-epimerase from yeast.
al. (1975) reported ú25 years ago, on the basis of their Biochemistry 7:1645–1654
studies of hGALE partially puriﬁed from control and Daude N, Gallaher TK, Zeschinigk M, Starzinski-Powitz A,
patient lymphoblasts, that, to achieve comparable levels Petry KG, Haworth IS, Reichardt JKV (1995) Molecular
of heat stability, the patient-derived enzyme required cloning, chracterization, and mapping of a full-length cDNA
encoding human UDP-galactose 4-epimerase. BiochemMolÇ10 times as much NAD/ as did the control. We pre-
Med 56:1–7sume that the apparent discrepancy between levels of
Elsevier JP, Wells L, Quimby BB, Fridovich-Keil JL (1996)exogenous NAD/ required by crude yeast lysates and
Heterodimer formation and activity in the human enzymepuriﬁed hGALE enzymes to achieve half-maximal activ-
galactose-1-phosphate uridylyltransferase. Proc Natl Acadity (ﬁg. 4 vs. ﬁg. 7) reﬂects largely the combined impacts
Sci USA 93:7166–7171of two factors: (1) the presence of many NAD/-binding
Frey PA (1996) The Leloir pathway: a mechanistic imperative
proteins in crude yeast lysates and (2) the likely presence for three enzymes to change the sterochemical conﬁguration
of at least trace quantities of NADH, a potent inhibitor of a single carbon in galactose. FASEB 10:461–470
of GALE (Maxwell 1957; Langer and Glaser 1974), in Fridovich-Keil JL, Jinks-Robertson S (1993) A yeast expres-
crude lysates. sion system for human galactose-1-phosphate uridylyl-
Differential dependence of the wild-type and N34S- transferase. Proc Natl Acad Sci USA 90:398–402
Fridovich-Keil JL, Langley SD, Mazur LA, Lennon JC, Demb-hGALE enzymes on exogenous NAD/ also likely ex-
ure PP, Elsas LJ II (1995a) Identiﬁcation and functionalplains the observation that crude cell lysates expressing
analysis of three distinct mutations in the human galactose-N34S-hGALE demonstrated only 70% wild-type activ-
1-phosphate uridyltransferase gene associated with galac-ity when assayed at 4 mM NAD/ (ﬁg. 5). Similar assays
tosemia in a single family. Am J Hum Genet 56:640–646performed at higher NAD/ concentrations (data not
Fridovich-Keil JL, Quimby, BB, Wells L, Mazur LA, Elseviershown) demonstrated less-pronounced differences be-
JP (1995b) Characterization of the N314D allele of human
tween samples. galactose-1-phosphate uridylyltransferase using a yeast ex-
pression system. Biochem Mol Med 56:121–130
Gentz R, Chen CH, Rosen CA (1989) Bioassay for trans-
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